Nuclear Medicine Therapeutics Market

Market Overview The global Nuclear Medicine Therapeutics Market is projected for substantial growth, expanding from USD 998.12 million in 2025 to USD 1734.74 million by 2031, at a robust CAGR of 9.65%. This market leverages radiopharmaceuticals to deliver precise, localized radiation doses for treating specific diseases, primarily in oncology and cardiology. These therapeutic agents operate by attaching to biological markers on cell surfaces, effectively eradicating malignant cells with high precision while minimizing harm to healthy surrounding tissues. The increasing global elderly population combined with a rising incidence of chronic diseases is a significant impetus for the market, fueling the demand for advanced precision treatments, as evidenced by approximately 50 million nuclear medicine procedures performed worldwide in 2024. Despite this positive outlook, a critical hurdle for market expansion is the inherent fragility of the global radioisotope supply chain. The exceptionally short physical half-lives of therapeutic isotopes necessitate an impeccably fast and faultless logistical system from production reactors to clinical delivery, leaving no room for delays. This reliance on a limited number of often outdated production facilities renders the supply vulnerable to disruptions, which can quickly lead to immediate shortages and consequently restrict patient access to these critical, time-sensitive therapies. Market Driver The escalating prevalence of cancer serves as the primary impetus for the global nuclear medicine therapeutics market, driving the necessity for targeted treatment modalities that surpass the efficacy of conventional chemotherapy. As the burden of oncological diseases grows, healthcare systems are increasingly emphasizing radiopharmaceuticals capable of both diagnosing and treating tumors concurrently. Projections from the International Agency for Research on Cancer in February 2024 indicate a significant rise in new cancer cases, from an estimated 20 million in 2022 to over 35 million by 2050. This projected surge critically underscores the urgent demand for scalable therapeutic solutions, particularly crucial for managing late-stage prostate and neuroendocrine cancers where treatment precision is paramount for optimal patient outcomes. Simultaneously, a substantial increase in public and private investment, frequently manifested through strategic acquisitions, is rapidly propelling market maturation and fostering innovation. Leading pharmaceutical companies are actively acquiring biotechnology firms with established radiopharmaceutical portfolios to secure a foothold in this rapidly expanding sector; for instance, AstraZeneca announced in March 2024 its definitive agreement to acquire Fusion Pharmaceuticals for approximately $2.4 billion to integrate advanced radioconjugates into its oncology pipeline. These capital injections are facilitating the expansion of manufacturing capabilities and the progression of novel alpha therapies through various clinical trials, while the reported sales of Novartis' radioligand therapy Pluvicto reaching USD 386 million in the third quarter of 2024 clearly demonstrate the commercial viability and increasing clinical adoption of these sophisticated treatments. Market Challenge The inherent fragility of the global radioisotope supply chain presents a significant impediment to the growth of the Global Nuclear Medicine Therapeutics Market. Given the extremely short physical half-lives of therapeutic isotopes, stockpiling is not feasible, necessitating a continuous, just-in-time delivery model that offers absolutely no tolerance for logistical errors. The market's heavy dependence on a limited number of aging research reactors means that any unscheduled maintenance or technical malfunctions can instantaneously disrupt the availability of critical treatments. This fundamental vulnerability introduces substantial market volatility, wherein even minor production halts translate directly into immediate downstream shortages for hospitals and clinics. This pervasive unreliability directly obstructs market expansion by frequently leading to procedure cancellations and eroding clinician confidence in the consistent availability of these vital therapies. For example, Nuclear Medicine Europe reported in 2024 that unexpected production delays resulted in supply shortfalls ranging from 50% to 100% across various global regions. Such severe interruptions compel healthcare providers to defer urgent oncological and cardiac interventions, thereby limiting patient throughput and diminishing revenue generation. Consequently, this pervasive unpredictability dissuades institutions from investing in new nuclear medicine infrastructure, ultimately hindering the broader commercial adoption of these precision treatments. Market Trends A significant market trend is the accelerating development of Targeted Alpha Therapy (TAT), marking a crucial evolution beyond traditional beta-emitters by harnessing the superior linear energy transfer of alpha particles. Unlike beta radiation, alpha particles deliver concentrated energy payloads over an extremely confined range, efficiently inducing irreparable double-strand DNA breaks in tumor cells while simultaneously minimizing collateral damage to surrounding healthy tissues. This enhanced therapeutic index is stimulating extensive clinical research and adoption, particularly for managing metastatic cancers that have become refractory to standard hormonal or beta-emitting radioligand therapies. Supporting this approach, Bayer's May 2025 announcement at ASCO 2025 indicated that integrating the alpha-emitter radium-223 with enzalutamide substantially improved outcomes, reducing the risk of radiological progression or death by 31% in patients with metastatic castration-resistant prostate cancer. Concurrently, the market is exhibiting a distinct trend towards the verticalization of radioisotope supply chains, as industry participants proactively consolidate manufacturing and distribution infrastructure to alleviate logistical vulnerabilities. By integrating production capabilities internally, companies are reducing their dependence on fragmented external suppliers, thereby establishing a more reliable "just-in-time" delivery system for short-lived isotopes. This strategic consolidation grants greater oversight concerning quality control, scheduling, and ensuring patient access, directly confronting the persistent challenge of isotope scarcity. The importance of such integrated logistics is underscored by major market transactions, notably CapVest Partners' November 2025 recapitalization of Curium at approximately $7 billion, explicitly attributing its end-to-end manufacturing and logistics capabilities as a primary determinant of its high valuation. Key Market Players * Actinium Pharmaceutical Inc. * Alpha Tau Medical Ltd * Bayer AG * Fusion Pharmaceuticals Inc. * IBA Radiopharma Solutions * RadioMedix Inc. * Telix Pharmaceuticals Ltd * NTP Radioisotopes Pty Ltd. * Bracco SpA * Cardinal Health Inc. * Nordion Inc. * Triad Isotopes Inc. Report Scope In this report, the Global Nuclear Medicine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Nuclear Medicine Therapeutics Market, By Type * Alpha Emitters * Beta Emitters * Brachytherapy # Nuclear Medicine Therapeutics Market, By Application * Oncology * Cardiology * Thyroid * Other Applications # Nuclear Medicine Therapeutics Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Nuclear Medicine Therapeutics Market. Available Customizations: Global Nuclear Medicine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).